antihemophilic factor viii (Recombinant), porcine sequence
Trade name: Obizur
Recombinant proteinapproved
Approved
Oct 23, 2014
Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII. — Wikipedia
Clinical trial activity
6 trials · 4 clinical orgs · 2 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
4
Phase 4
0
Earliest trial started May 1, 2005 (NCT00245245)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Coagulation factor VIIIAGONIST
F8 agonist
- Coagulation factor VIIIEXOGENOUS PROTEIN
Coagulation factor VIII exogenous protein
- Coagulation factor VIIISupplementation
F8 supplementation
Approval history
- approvedOct 23, 2014
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSusoctocog alfa ↗
- NCATS6892UQT2GK ↗
- ChEMBLCHEMBL5315075 ↗
Also known as
- antihemophilic factor (recombinant), porcine sequence
- obi-1
- obizur
- obizur
- obizur
- obizur
- porcine coagulation factor viii
- recombinant porcine antihemophilic factor
- susoctocog alfa
- susoctocog alfa
- susoctocog alfa
- susoctocog alfa
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04580407 | Phase 2/Phase 3 (Phase 3) | Dec 15, 2020 | Takeda |
| NCT02895945 | Phase 3 | Dec 22, 2016 | Baxalta |
| NCT01968655 | N/A | Oct 21, 2013 | Baxalta |
| NCT01434511 | Phase 3 | Aug 1, 2011 | Baxalta |
| NCT01178294 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2010 | Baxalta |
| NCT00245245 | Phase 2 | May 1, 2005 | Ipsen, Octagen |
Showing 6 of 6 trials
Page 1 / 1